SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAiGenome-based Drug Discovery

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2158069

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2158069

CRISPR Market by Offering (Products [Kits, Enzymes, Libraries], Services [gRNA Synthesis, Cell Line Development, Screening, Validation]), Application (Drug Discovery, Development, Agriculture), End User, Competition, Region - Global Forecast to 2031

PUBLISHED:
PAGES: 319 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The CRISPR market is expected to reach USD 6.12 billion in 2031 from USD 3.48 billion in 2026, at a CAGR of 12.0% during the forecast period. Market growth is driven by the increasing adoption of CRISPR-based genome editing in drug discovery, functional genomics, cell and gene therapy, genetic disease research, and molecular diagnostics.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsOffering, Product Type, Product End User, Service, Service End User and Application
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Advancements in base editing, prime editing, RNA editing, and high-fidelity CRISPR systems are further expanding the range of genome-editing applications. Increasing demand for precise, scalable, and reproducible genome-editing workflows is also supporting the adoption of CRISPR products and services.

CRISPR Market - IMG1

"The CRISPR kits & enzymes segment is expected to grow at the highest CAGR during the forecast period"

The CRISPR kits & enzymes segment is expected to grow at the highest CAGR during the forecast period, driven by increasing demand for ready-to-use genome-editing reagents and enzymes across research and genome-engineering workflows. These products support applications such as guide RNA-based editing, gene knockout, gene activation, editing validation, and development of advanced genome-editing systems. Growing adoption of high-throughput screening, functional genomics, and next-generation editors is increasing the need for specialized CRISPR kits and enzymes. Continued development of high-fidelity nucleases, base editors, prime editors, and other engineered editing systems is expected to further support demand for advanced CRISPR products.

"The drug discovery & development segment holds the largest share of the market"

The drug discovery & development segment holds the largest share of the CRISPR market, supported by the increasing use of genome editing for target identification, target validation, disease-model development, functional genomics, and drug screening. Pharmaceutical and biotechnology companies increasingly use CRISPR-based knockout, activation, inhibition, and screening approaches to investigate gene function and disease mechanisms and identify potential therapeutic targets. The growing use of CRISPR in cell and gene therapy development and precision medicine is further supporting demand for genome-editing products, screening platforms, and related services.

"The US is expected to grow at the highest CAGR during the forecast period"

The US is expected to grow at the highest CAGR in the CRISPR market due to its strong presence of leading genome-editing companies, advanced biomedical research infrastructure, and high adoption of CRISPR technologies across research and therapeutic applications. Rising use of CRISPR in drug discovery, functional genomics, cell and gene therapy, genetic disease research, and precision medicine is driving market growth. Technologies such as CRISPR-Cas systems, base editing, prime editing, guide RNA design, and genome-editing screening and validation are increasingly used across pharmaceutical companies, biotechnology firms, academic institutes, and research organizations, further supporting demand.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 70% and Demand Side - 30%
  • By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
  • By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio Inc. (Japan), Creative Biogene (US), Fujian SunvBiotech Co., Ltd. (China), EditCR (US), Caribou Biosciences, Inc. (US), Lonza (Switzerland), and Danaher Corporation (US) are some of the key companies offering CRISPR products and services.

Research Coverage

This research report categorizes the CRISPR market by offering (products and services), product type (CRISPR kits & enzymes, CRISPR libraries, and other products), product end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), service type (gRNA synthesis & cell line development, screening & validation, and other services), service end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), application (drug discovery & development, agriculture, and other applications), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the CRISPR market. A comprehensive analysis of key industry players provides insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the CRISPR market. This report also includes a competitive analysis of emerging startups in the CRISPR industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases, expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the market growth
  • Product Development/Innovation: Detailed insights into newly launched products and innovations in the CRISPR market
  • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CRISPR market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Revvity (US), Danaher (US), and Lonza (Switzerland), among others, for the CRISPR market
Show more
Product Code: BT 6746

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN CRISPR MARKET
  • 2.4 HIGH-GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 CRISPR MARKET OVERVIEW
  • 3.2 NORTH AMERICA: CRISPR MARKET, BY SERVICE
  • 3.3 CRISPR MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 3.4 CRISPR MARKET SHARE, BY OFFERING, 2026 VS. 2031 (%)

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Growing demand for CRISPR-based gene therapies
      • 4.2.1.2 Advancements in CRISPR technology
      • 4.2.1.3 Growing government and private investments and funding for CRISPR technology
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Technical challenges associated with CRISPR technology
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Development of new vaccines and treatments for genetic diseases
      • 4.2.3.2 Expanding industrial and agricultural applications of CRISPR
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Regulatory hurdles for CRISPR advancements
  • 4.3 UNMET NEEDS & WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 BARGAINING POWER OF SUPPLIERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
    • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
    • 5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
    • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2023-2025
    • 5.5.2 INDICATIVE PRICE TREND FOR CRISPR SERVICES
    • 5.5.3 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025
  • 5.6 TRADE ANALYSIS
    • 5.6.1 IMPORT SCENARIO (HS CODE 3822.00)
    • 5.6.2 EXPORT SCENARIO (HS CODE 3822.00)
  • 5.7 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.9 INVESTMENT & FUNDING SCENARIO
  • 5.10 CASE STUDY ANALYSIS
    • 5.10.1 CRISPR-CAS9 EDITING DEMONSTRATES DURABLE LIPID REDUCTION
    • 5.10.2 IN VIVO CRISPR EDITING SIGNIFICANTLY REDUCES HEREDITARY ANGIOEDEMA ATTACKS
  • 5.11 IMPACT OF 2025 US TARIFFS ON CRISPR MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON COUNTRY/REGION
      • 5.11.4.1 US
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
      • 5.11.4.4 Rest of the World
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Pharmaceutical & biotech companies
      • 5.11.5.2 Contract Research Organizations (CROs)
      • 5.11.5.3 Academic & research institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 TECHNOLOGY ANALYSIS
    • 6.1.1 KEY TECHNOLOGIES
      • 6.1.1.1 CRISPR-Cas systems
      • 6.1.1.2 gRNA design & optimization
      • 6.1.1.3 High-throughput CRISPR screening
    • 6.1.2 COMPLEMENTARY TECHNOLOGIES
      • 6.1.2.1 Synthetic biology
      • 6.1.2.2 Single-cell genomics
      • 6.1.2.3 Next-generation sequencing
    • 6.1.3 ADJACENT TECHNOLOGIES
      • 6.1.3.1 Stem cell engineering
      • 6.1.3.2 Synthetic DNA & gene synthesis
      • 6.1.3.3 Microfluidics
  • 6.2 TECHNOLOGY ROADMAP
  • 6.3 PATENT ANALYSIS
    • 6.3.1 METHODOLOGY
    • 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
    • 6.3.3 LIST OF KEY PATENTS
  • 6.4 FUTURE APPLICATIONS
  • 6.5 IMPACT OF AI/GEN AI ON CRISPR MARKET
    • 6.5.1 TOP USE CASES & MARKET POTENTIAL
    • 6.5.2 BEST PRACTICES IN AI-ENABLED CRISPR WORKFLOWS
    • 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN CRISPR MARKET
    • 6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS
    • 6.5.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED CRISPR TECHNOLOGIES

7 SUSTAINABILITY & REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 INDUSTRY STANDARDS
      • 7.1.2.1 North America
        • 7.1.2.1.1 US
        • 7.1.2.1.2 Canada
      • 7.1.2.2 Europe
        • 7.1.2.2.1 Germany
        • 7.1.2.2.2 UK
        • 7.1.2.2.3 France
      • 7.1.2.3 Asia Pacific
        • 7.1.2.3.1 Japan
        • 7.1.2.3.2 China
      • 7.1.2.4 Latin America
        • 7.1.2.4.1 Brazil
      • 7.1.2.5 Middle East & Africa
        • 7.1.2.5.1 GCC Countries
        • 7.1.2.5.2 South Africa
  • 7.2 SUSTAINABILITY INITIATIVES
  • 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
  • 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 CRISPR MARKET: BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 CRISPR MARKET, BY OFFERING

  • 9.1 INTRODUCTION
  • 9.2 PRODUCTS
    • 9.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • 9.3 SERVICES
    • 9.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET

10 CRISPR PRODUCTS MARKET, BY TYPE

  • 10.1 INTRODUCTION
  • 10.2 CRISPR KITS & ENZYMES
    • 10.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
  • 10.3 CRISPR LIBRARIES
    • 10.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH
  • 10.4 OTHER PRODUCTS

11 CRISPR PRODUCTS MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
    • 11.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
  • 11.4 OTHER END USERS

12 CRISPR MARKET, BY SERVICE

  • 12.1 INTRODUCTION
    • 12.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
      • 12.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
    • 12.1.2 SCREENING & VALIDATION
      • 12.1.2.1 Rapid advancements in CRISPR technology to drive growth
  • 12.2 OTHER SERVICES

13 CRISPR SERVICES MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 13.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • 13.3 ACADEMIC & RESEARCH INSTITUTES
    • 13.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
  • 13.4 OTHER END USERS

14 CRISPR MARKET, BY APPLICATION

  • 14.1 INTRODUCTION
  • 14.2 DRUG DISCOVERY & DEVELOPMENT
    • 14.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • 14.3 AGRICULTURE
    • 14.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
  • 14.4 OTHER APPLICATIONS

15 CRISPR MARKET, BY REGION

  • 15.1 INTRODUCTION
  • 15.2 NORTH AMERICA
    • 15.2.1 US
      • 15.2.1.1 Increasing demand for CRISPR products and services across various industries to drive growth
    • 15.2.2 CANADA
      • 15.2.2.1 Increasing demand for gene-editing technologies to boost growth
  • 15.3 EUROPE
    • 15.3.1 GERMANY
      • 15.3.1.1 Rapidly increasing biotechnology sector to support growth
    • 15.3.2 UK
      • 15.3.2.1 Significant government investments in genomics research to propel growth
    • 15.3.3 FRANCE
      • 15.3.3.1 Increasing demand for targeted therapies and personalized medicine to propel growth
    • 15.3.4 ITALY
      • 15.3.4.1 Increasing demand for innovative therapeutic solutions to drive growth
    • 15.3.5 SPAIN
      • 15.3.5.1 Increasing demand for precision medicine to drive growth
    • 15.3.6 REST OF EUROPE
  • 15.4 ASIA PACIFIC
    • 15.4.1 CHINA
      • 15.4.1.1 Increasing investments in R&D to drive growth
    • 15.4.2 JAPAN
      • 15.4.2.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
    • 15.4.3 INDIA
      • 15.4.3.1 Increasing prevalence of genetic disorders to support growth
    • 15.4.4 AUSTRALIA
      • 15.4.4.1 Growing clinical translation and advancements in CRISPR technologies to support growth
    • 15.4.5 SOUTH KOREA
      • 15.4.5.1 Advancements in next-generation CRISPR and precision RNA editing to support growth
    • 15.4.6 REST OF ASIA PACIFIC
  • 15.5 LATIN AMERICA
    • 15.5.1 BRAZIL
      • 15.5.1.1 Growing adoption of genome technologies to propel growth
    • 15.5.2 REST OF LATIN AMERICA
  • 15.6 MIDDLE EAST
    • 15.6.1 GCC COUNTRIES
      • 15.6.1.1 Saudi Arabia
        • 15.6.1.1.1 Regulatory support and expanding advanced-therapy infrastructure to boost market
      • 15.6.1.2 UAE
        • 15.6.1.2.1 Precision medicine investment and advanced clinical infrastructure to aid market growth
      • 15.6.1.3 Rest of GCC Countries
    • 15.6.2 REST OF MIDDLE EAST
  • 15.7 AFRICA
    • 15.7.1 EXPANDING AGRICULTURAL BIOTECHNOLOGY AND GENOMICS RESEARCH TO PROPEL MARKET

16 COMPETITIVE LANDSCAPE

  • 16.1 INTRODUCTION
  • 16.2 KEY PLAYER STRATEGY/RIGHT TO WIN, JANUARY 2023-SEPTEMBER 2026
    • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, JANUARY 2023-SEPTEMBER 2026
  • 16.3 REVENUE ANALYSIS, 2021-2025
  • 16.4 MARKET SHARE ANALYSIS, 2025
  • 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 16.5.1 STARS
    • 16.5.2 EMERGING LEADERS
    • 16.5.3 PERVASIVE PLAYERS
    • 16.5.4 PARTICIPANTS
    • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 16.5.5.1 Company footprint
      • 16.5.5.2 Region footprint
      • 16.5.5.3 Product footprint
      • 16.5.5.4 Service footprint
      • 16.5.5.5 Application footprint
  • 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 16.6.1 PROGRESSIVE COMPANIES
    • 16.6.2 RESPONSIVE COMPANIES
    • 16.6.3 DYNAMIC COMPANIES
    • 16.6.4 STARTING BLOCKS
    • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
      • 16.6.5.1 Detailed list of key startups/SMEs
      • 16.6.5.2 Competitive benchmarking of key startups/SMEs
  • 16.7 COMPANY VALUATION & FINANCIAL METRICS
    • 16.7.1 COMPANY VALUATION & FINANCIAL METRICS
    • 16.7.2 COMPANY VALUATION & FINANCIAL METRICS
  • 16.8 BRAND COMPARISON
  • 16.9 COMPETITIVE SCENARIO
    • 16.9.1 PRODUCT LAUNCHES
    • 16.9.2 DEALS
    • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

  • 17.1 KEY PLAYERS
    • 17.1.1 THERMO FISHER SCIENTIFIC INC.
      • 17.1.1.1 Business overview
      • 17.1.1.2 Products & services offered
      • 17.1.1.3 Recent developments
        • 17.1.1.3.1 Expansions
      • 17.1.1.4 MnM view
        • 17.1.1.4.1 Key strengths
        • 17.1.1.4.2 Strategic choices
        • 17.1.1.4.3 Weaknesses & competitive threats
    • 17.1.2 MERCK KGAA
      • 17.1.2.1 Business overview
      • 17.1.2.2 Products & services offered
      • 17.1.2.3 Recent developments
        • 17.1.2.3.1 Product launches
        • 17.1.2.3.2 Deals
      • 17.1.2.4 MnM view
        • 17.1.2.4.1 Key strengths
        • 17.1.2.4.2 Strategic choices
        • 17.1.2.4.3 Weaknesses & competitive threats
    • 17.1.3 AGILENT TECHNOLOGIES, INC.
      • 17.1.3.1 Business overview
      • 17.1.3.2 Products & services offered
      • 17.1.3.3 Recent developments
        • 17.1.3.3.1 Deals
        • 17.1.3.3.2 Expansions
      • 17.1.3.4 MnM view
        • 17.1.3.4.1 Key strengths
        • 17.1.3.4.2 Strategic choices
        • 17.1.3.4.3 Weaknesses & competitive threats
    • 17.1.4 GENSCRIPT
      • 17.1.4.1 Business overview
      • 17.1.4.2 Products & services offered
      • 17.1.4.3 Recent developments
        • 17.1.4.3.1 Deals
        • 17.1.4.3.2 Expansions
      • 17.1.4.4 MnM view
        • 17.1.4.4.1 Key strengths
        • 17.1.4.4.2 Strategic choices
        • 17.1.4.4.3 Weaknesses & competitive threats
    • 17.1.5 REVVITY
      • 17.1.5.1 Business overview
      • 17.1.5.2 Products & services offered
      • 17.1.5.3 Recent developments
        • 17.1.5.3.1 Product launches
        • 17.1.5.3.2 Deals
    • 17.1.6 LONZA
      • 17.1.6.1 Business overview
      • 17.1.6.2 Products & services offered
      • 17.1.6.3 Recent developments
        • 17.1.6.3.1 Product launches
        • 17.1.6.3.2 Deals
        • 17.1.6.3.3 Expansions
    • 17.1.7 DANAHER CORPORATION
      • 17.1.7.1 Business overview
      • 17.1.7.2 Products & services offered
      • 17.1.7.3 Recent developments
        • 17.1.7.3.1 Product launches
        • 17.1.7.3.2 Deals
    • 17.1.8 TAKARA BIO INC.
      • 17.1.8.1 Business overview
      • 17.1.8.2 Products & services offered
      • 17.1.8.3 Recent developments
        • 17.1.8.3.1 Deals
    • 17.1.9 CREATIVE BIOGENE
      • 17.1.9.1 Business overview
      • 17.1.9.2 Products & services offered
      • 17.1.9.3 Recent developments
        • 17.1.9.3.1 Service launches
    • 17.1.10 FUJIAN SUNYBIOTECH CO., LTD.
      • 17.1.10.1 Business overview
      • 17.1.10.2 Products & services offered
    • 17.1.11 EDITCO
      • 17.1.11.1 Business overview
      • 17.1.11.2 Products & services offered
      • 17.1.11.3 Recent financials
        • 17.1.11.3.1 Deals
    • 17.1.12 CARIBOU BIOSCIENCES, INC.
      • 17.1.12.1 Business overview
      • 17.1.12.2 Products & services offered
      • 17.1.12.3 Recent developments
        • 17.1.12.3.1 Deals
    • 17.1.13 DEMEETRA AGBIO
      • 17.1.13.1 Business overview
      • 17.1.13.2 Products & services offered
      • 17.1.13.3 Recent developments
        • 17.1.13.3.1 Deals
    • 17.1.14 ORIGENE TECHNOLOGIES, INC.
      • 17.1.14.1 Business overview
      • 17.1.14.2 Products & services offered
    • 17.1.15 CELLECTA, INC.
      • 17.1.15.1 Business overview
      • 17.1.15.2 Products & services offered
  • 17.2 OTHER PLAYERS
    • 17.2.1 MAMMOTH BIOSCIENCES, INC.
    • 17.2.2 APPLIED STEMCELL
    • 17.2.3 NEW ENGLAND BIOLABS
    • 17.2.4 TOOLGEN, INC.
    • 17.2.5 GENECOPOEIA, INC.
    • 17.2.6 TWIST BIOSCIENCE
    • 17.2.7 SYNTHEGO
    • 17.2.8 EGENESIS
    • 17.2.9 MANUS BIO
    • 17.2.10 PRECISION BIOSCIENCES

18 RESEARCH METHODOLOGY

  • 18.1 RESEARCH DATA
    • 18.1.1 SECONDARY DATA
    • 18.1.2 PRIMARY RESEARCH
  • 18.2 MARKET SIZE ESTIMATION
    • 18.2.1 GLOBAL MARKET ESTIMATION
      • 18.2.1.1 Insights from primary experts
    • 18.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
  • 18.3 MARKET GROWTH RATE PROJECTION
  • 18.4 DATA TRIANGULATION
  • 18.5 RESEARCH ASSUMPTIONS
  • 18.6 RESEARCH LIMITATIONS
  • 18.7 RISK ANALYSIS

19 APPENDIX

  • 19.1 DISCUSSION GUIDE
  • 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 19.3 CUSTOMIZATION OPTIONS
  • 19.4 RELATED REPORTS
  • 19.5 AUTHOR DETAILS
Show more
Product Code: BT 6746

List of Tables

  • TABLE 1 CRISPR MARKET: IMPACT ANALYSIS
  • TABLE 2 CRISPR MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 3 CRISPR MARKET: ROLE OF PLAYERS IN ECOSYSTEM
  • TABLE 4 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2023-2025
  • TABLE 5 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025 (USD)
  • TABLE 6 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 7 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 8 CRISPR MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 9 RECIPROCAL TARIFF RATES ADJUSTED BY US
  • TABLE 10 KEY TARIFFS ON PHARMACEUTICAL PRODUCTS
  • TABLE 11 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
  • TABLE 12 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015-2025
  • TABLE 13 LIST OF KEY PATENTS IN CRISPR MARKET, 2023-2025
  • TABLE 14 CASE STUDIES OF AI IMPLEMENTATION IN CRISPR MARKET
  • TABLE 15 CLIENTS' READINESS TO ADOPT AI-INTEGRATED CRISPR TECHNOLOGIES
  • TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • TABLE 22 KEY BUYING CRITERIA, BY END USER (PRODUCTS)
  • TABLE 23 KEY BUYING CRITERIA, BY END USER (SERVICES)
  • TABLE 24 CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 25 CRISPR PRODUCTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 26 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 27 EUROPE: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 29 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 30 MIDDLE EAST: CRISPR PRODUCTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 31 GCC COUNTRIES: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 32 CRISPR SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 33 NORTH AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 34 EUROPE: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 36 LATIN AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 37 MIDDLE EAST: CRISPR SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 38 GCC COUNTRIES: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 39 CRISPR PRODUCTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 40 CRISPR KITS & ENZYMES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 41 NORTH AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 42 EUROPE: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 44 LATIN AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 45 MIDDLE EAST: CRISPR KITS & ENZYMES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 46 GCC COUNTRIES: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 47 CRISPR LIBRARIES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 48 NORTH AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 49 EUROPE: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 51 LATIN AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 52 MIDDLE EAST: CRISPR LIBRARIES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 53 GCC COUNTRIES: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 54 OTHER CRISPR PRODUCTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 55 NORTH AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 56 EUROPE: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 58 LATIN AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 59 MIDDLE EAST: OTHER CRISPR PRODUCTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 60 GCC COUNTRIES: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 61 CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 62 CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 63 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 64 EUROPE: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 66 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 67 MIDDLE EAST: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 68 GCC COUNTRIES: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 69 CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 70 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 71 EUROPE: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 73 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 74 MIDDLE EAST: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 75 GCC COUNTRIES: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 76 CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 77 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 78 EUROPE: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 80 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 81 MIDDLE EAST: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 82 GCC COUNTRIES: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 83 CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 84 CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 85 NORTH AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 86 EUROPE: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 88 LATIN AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 89 MIDDLE EAST: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 90 GCC COUNTRIES: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 91 CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 93 EUROPE: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 95 LATIN AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 96 MIDDLE EAST: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 97 GCC COUNTRIES: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 98 OTHER CRISPR SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 99 NORTH AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 100 EUROPE: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 102 LATIN AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 103 MIDDLE EAST: OTHER CRISPR SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 104 GCC COUNTRIES: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 105 CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 106 CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 107 NORTH AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 108 EUROPE: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 110 LATIN AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 111 MIDDLE EAST: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 112 GCC COUNTRIES: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 113 CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 114 NORTH AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 115 EUROPE: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 117 LATIN AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 118 MIDDLE EAST: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 120 CRISPR SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 121 NORTH AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 122 EUROPE: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 124 LATIN AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 125 MIDDLE EAST: CRISPR SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 126 GCC COUNTRIES: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 127 CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 128 CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 129 NORTH AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 130 EUROPE: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 132 LATIN AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 133 MIDDLE EAST: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 134 GCC COUNTRIES: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 135 CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 136 NORTH AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 137 EUROPE: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 139 LATIN AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 140 MIDDLE EAST: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 141 GCC COUNTRIES: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 142 CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 143 NORTH AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 144 EUROPE: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 146 LATIN AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 147 MIDDLE EAST: CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 148 GCC COUNTRIES: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 149 CRISPR MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 150 NORTH AMERICA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 151 NORTH AMERICA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 152 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 153 NORTH AMERICA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 154 NORTH AMERICA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 155 NORTH AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 156 US: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 157 US: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 158 US: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 159 US: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 160 US: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 161 US: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 162 CANADA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 163 CANADA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 164 CANADA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 165 CANADA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 166 CANADA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 167 CANADA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 168 EUROPE: CRISPR MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 169 EUROPE: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 170 EUROPE: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 171 EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 172 EUROPE: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 173 EUROPE: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 174 EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 175 GERMANY: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 176 GERMANY: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 177 GERMANY: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 178 GERMANY: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 179 GERMANY: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 180 GERMANY: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 181 UK: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 182 UK: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 183 UK: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 184 UK: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 185 UK: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 186 UK: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 187 FRANCE: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 188 FRANCE: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 189 FRANCE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 190 FRANCE: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 191 FRANCE: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 192 FRANCE: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 193 ITALY: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 194 ITALY: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 195 ITALY: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 196 ITALY: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 197 ITALY: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 198 ITALY: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 199 SPAIN: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 200 SPAIN: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 201 SPAIN: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 202 SPAIN: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 203 SPAIN: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 204 SPAIN: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 205 REST OF EUROPE: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 206 REST OF EUROPE: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 207 REST OF EUROPE: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 208 REST OF EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 209 REST OF EUROPE: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 210 REST OF EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: CRISPR MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 218 CHINA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 219 CHINA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 220 CHINA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 221 CHINA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 222 CHINA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 223 CHINA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 224 JAPAN: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 225 JAPAN: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 226 JAPAN: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 227 JAPAN: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 228 JAPAN: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 229 JAPAN: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 230 INDIA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 231 INDIA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 232 INDIA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 233 INDIA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 234 INDIA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 235 INDIA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 236 AUSTRALIA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 237 AUSTRALIA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 238 AUSTRALIA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 239 AUSTRALIA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 240 AUSTRALIA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 241 AUSTRALIA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 242 SOUTH KOREA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 243 SOUTH KOREA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 244 SOUTH KOREA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 245 SOUTH KOREA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 246 SOUTH KOREA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 247 SOUTH KOREA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 248 REST OF ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 249 REST OF ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 250 REST OF ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 251 REST OF ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 252 REST OF ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 253 REST OF ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 254 LATIN AMERICA: CRISPR MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 255 LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 256 LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 257 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 258 LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 259 LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 260 LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 261 BRAZIL: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 262 BRAZIL: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 263 BRAZIL: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 264 BRAZIL: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 265 BRAZIL: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 266 BRAZIL: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 267 REST OF LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 268 REST OF LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 269 REST OF LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 270 REST OF LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 271 REST OF LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 272 REST OF LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 273 MIDDLE EAST: CRISPR MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 274 MIDDLE EAST: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 275 MIDDLE EAST: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 276 MIDDLE EAST: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 277 MIDDLE EAST: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 278 MIDDLE EAST: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 279 MIDDLE EAST: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 280 GCC COUNTRIES: CRISPR MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 281 GCC COUNTRIES: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 282 GCC COUNTRIES: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 283 GCC COUNTRIES: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 284 GCC COUNTRIES: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 285 GCC COUNTRIES: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 286 GCC COUNTRIES: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 287 SAUDI ARABIA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 288 SAUDI ARABIA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 289 SAUDI ARABIA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 290 SAUDI ARABIA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 291 SAUDI ARABIA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 292 SAUDI ARABIA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 293 UAE: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 294 UAE: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 295 UAE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 296 UAE: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 297 UAE: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 298 UAE: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 299 REST OF GCC COUNTRIES: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 300 REST OF GCC COUNTRIES: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 301 REST OF GCC COUNTRIES: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 302 REST OF GCC COUNTRIES: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 303 REST OF GCC COUNTRIES: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 304 REST OF GCC COUNTRIES: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 305 REST OF MIDDLE EAST: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 306 REST OF MIDDLE EAST: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 307 REST OF MIDDLE EAST: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 308 REST OF MIDDLE EAST: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 309 REST OF MIDDLE EAST: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 310 REST OF MIDDLE EAST: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 311 AFRICA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 312 AFRICA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 313 AFRICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 314 AFRICA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 315 AFRICA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 316 AFRICA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 317 STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, JANUARY 2023-SEPTEMBER 2026
  • TABLE 318 CRISPR MARKET: DEGREE OF COMPETITION
  • TABLE 319 CRISPR MARKET: REGION FOOTPRINT
  • TABLE 320 CRISPR MARKET: PRODUCT FOOTPRINT
  • TABLE 321 CRISPR MARKET: SERVICE FOOTPRINT
  • TABLE 322 CRISPR MARKET: APPLICATION FOOTPRINT
  • TABLE 323 CRISPR MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 324 CRISPR MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 325 CRISPR MARKET: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 326 CRISPR MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 327 CRISPR MARKET: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 328 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 329 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 330 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 331 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 332 MERCK KGAA: PRODUCTS & SERVICES OFFERED
  • TABLE 333 MERCK KGAA: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 334 MERCK KGAA: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 335 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 336 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 337 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 338 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 339 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 340 GENSCRIPT: PRODUCTS & SERVICES OFFERED
  • TABLE 341 GENSCRIPT: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 342 GENSCRIPT: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 343 REVVITY: COMPANY OVERVIEW
  • TABLE 344 REVVITY: PRODUCTS & SERVICES OFFERED
  • TABLE 345 REVVITY: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 346 REVVITY: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 347 LONZA: COMPANY OVERVIEW
  • TABLE 348 LONZA: PRODUCTS & SERVICES OFFERED
  • TABLE 349 LONZA: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 350 LONZA: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 351 LONZA: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 352 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 353 DANAHER CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 354 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 355 DANAHER CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 356 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 357 TAKARA BIO INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 358 TAKARA BIO INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 359 CREATIVE BIOGENE: COMPANY OVERVIEW
  • TABLE 360 CREATIVE BIOGENE: PRODUCTS & SERVICES OFFERED
  • TABLE 361 CREATIVE BIOGENE: SERVICE LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 362 FUJIAN SUNYBIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 363 FUJIAN SUNYBIOTECH CO., LTD.: PRODUCTS & SERVICES OFFERED
  • TABLE 364 EDITCO: COMPANY OVERVIEW
  • TABLE 365 EDITCO: PRODUCTS & SERVICES OFFERED
  • TABLE 366 EDITCO: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 367 CARIBOU BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 368 CARIBOU BIOSCIENCES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 369 CARIBOU BIOSCIENCES, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 370 DEMEETRA AGBIO: COMPANY OVERVIEW
  • TABLE 371 DEMEETRA AGBIO: PRODUCTS & SERVICES OFFERED
  • TABLE 372 DEMEETRA AGBIO: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 373 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 374 ORIGENE TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 375 CELLECTA, INC.: COMPANY OVERVIEW
  • TABLE 376 CELLECTA, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 377 MAMMOTH BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 378 APPLIED STEMCELL: COMPANY OVERVIEW
  • TABLE 379 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
  • TABLE 380 TOOLGEN, INC.: COMPANY OVERVIEW
  • TABLE 381 GENECOPOEIA, INC.: COMPANY OVERVIEW
  • TABLE 382 TWIST BIOSCIENCE: COMPANY OVERVIEW
  • TABLE 383 SYNTHEGO: COMPANY OVERVIEW
  • TABLE 384 EGENESIS: COMPANY OVERVIEW
  • TABLE 385 MANUS BIO: COMPANY OVERVIEW
  • TABLE 386 PRECISION BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 387 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 388 CRISPR MARKET: RISK ANALYSIS

List of Figures

  • FIGURE 1 CRISPR MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 MARKET SCENARIO
  • FIGURE 3 GLOBAL CRISPR MARKET, 2023-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, 2023-2026
  • FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF CRISPR MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS IN CRISPR MARKET, 2026-2031
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CRISPR MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 8 GROWING INVESTMENTS IN CRISPR TECHNOLOGY AND EXPANDING APPLICATIONS TO DRIVE MARKET GROWTH
  • FIGURE 9 PRODUCTS ACCOUNTED FOR LARGEST SHARE OF CRISPR MARKET IN NORTH AMERICA IN 2025
  • FIGURE 10 CHINA TO BE FASTEST-GROWING MARKET IN GLOBAL CRISPR MARKET DURING FORECAST PERIOD
  • FIGURE 11 PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 12 CRISPR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13 TOP 10 LEADING CRISPR STARTUPS BASED ON INVESTMENTS RAISED IN 2024
  • FIGURE 14 CRISPR MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 15 CRISPR MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 16 CRISPR MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 17 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY KEY PLAYER (2025)
  • FIGURE 18 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025 (USD)
  • FIGURE 19 CRISPR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 20 INVESTMENT & FUNDING SCENARIO, 2023-2025 (USD MILLION)
  • FIGURE 21 PATENT APPLICATIONS IN CRISPR MARKET, JANUARY 2015-DECEMBER 2025
  • FIGURE 22 IMPACT OF AI/GEN AI ON CRISPR MARKET
  • FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • FIGURE 24 KEY BUYING CRITERIA OF END USERS FOR CRISPR PRODUCTS
  • FIGURE 25 KEY SELECTION CRITERIA OF END USERS FOR CRISPR SERVICES
  • FIGURE 26 NORTH AMERICA: CRISPR MARKET SNAPSHOT
  • FIGURE 27 ASIA PACIFIC: CRISPR MARKET SNAPSHOT
  • FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2021-2025
  • FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2025
  • FIGURE 30 CRISPR MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 31 CRISPR MARKET: COMPANY FOOTPRINT
  • FIGURE 32 CRISPR MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 34 EV/EBITDA OF KEY VENDORS
  • FIGURE 35 CRISPR MARKET: BRAND COMPARISON
  • FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025)
  • FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 39 GENSCRIPT: COMPANY SNAPSHOT (2025)
  • FIGURE 40 REVVITY: COMPANY SNAPSHOT (2025)
  • FIGURE 41 LONZA: COMPANY SNAPSHOT (2025)
  • FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 43 TAKARA BIO INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 44 CARIBOU BIOSCIENCES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 45 CRISPR MARKET: RESEARCH DESIGN
  • FIGURE 46 CRISPR MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 47 CRISPR MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
  • FIGURE 48 CRISPR MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
  • FIGURE 49 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2025)
  • FIGURE 50 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 52 CRISPR MARKET: CAGR PROJECTIONS
  • FIGURE 53 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!